A Novel Controlled Release Immunosensor based on Benzimidazole Functionalized SiO2 and Cyclodextrin Functionalized...

Area of Science:

• Biomedical Engineering
• Analytical Chemistry
• Materials Science

Background:

• Squamous cell carcinoma antigen (SCCA) is a biomarker for certain cancers.
• Early and accurate detection of SCCA is crucial for effective treatment.
• Existing detection methods may lack sensitivity or require complex procedures.

Purpose of the Study:

• To develop a novel controlled release system-based sandwich-type immunosensor for SCCA detection.
• To utilize pH as a trigger for controlled release of a signaling molecule.
• To achieve high sensitivity and selectivity in SCCA detection.

Main Methods:

• Fabrication of a novel immunosensor using 1-methyl-1H-benzimidazole functionalized mesoporous SiO2 (MBI-MS) to load methylene blue (MB).
• Utilizing β-cyclodextrin functionalized gold (CD-Au) as a gatekeeper for MB encapsulation and antibody capture.
• Employing a pH stimulus (below 7.0) to trigger the release of MB for detection via square wave voltammetry.

Main Results:

• The controlled release immunosensor demonstrated a wide linear range for SCCA detection (0.001 to 20 ng·mL⁻¹).
• A low detection limit of 0.25 pg·mL⁻¹ was achieved.
• The immunosensor exhibited good reproducibility and selectivity.

Conclusions:

• The developed pH-triggered controlled release immunosensor is effective for SCCA detection.
• The system shows significant potential for clinical research and diagnostics.
• The novel design offers a sensitive and selective platform for biomarker detection.